Clinical trial
A Study of the Safety and Effectiveness of Liquid Certolizumab Pegol in the…
NCT00160641 · UCB Pharma, Industry · Completed
Key facts
| NCT number | NCT00160641 |
|---|---|
| Title | A Study of the Safety and Effectiveness of Liquid Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis |
| Official title | A Phase III Multi-center, Open-label, Follow-up Study, to Assess the Safety and Efficacy of Liquid Certolizumab Pegol as Additional Medication to Methotrexate, in the Treatment of Signs and Symptoms and in the Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis Who Participated… |
| Lead sponsor | UCB Pharma, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Rheumatoid Arthritis |
| Intervention type | Biological |
| Interventions | Certolizumab Pegol |
| Enrollment | 567 |
| Start date | Nov 1, 2005 |
| Primary completion | Feb 1, 2012 |
| Completion | Feb 1, 2012 |
| First posted | Sep 12, 2005 |
| Last update posted | Mar 27, 2020 |
| Countries | Bulgaria, Croatia, Czechia, Estonia, Israel, Latvia, Lithuania, Poland, Russia, Serbia, Slovakia, Ukraine and 1 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: